Research programme: protein kinase C-delta inhibitor therapeutics - BriaCell Therapeutics

Drug Profile

Research programme: protein kinase C-delta inhibitor therapeutics - BriaCell Therapeutics

Alternative Names: PKCd inhibitors - BriaCell Therapeutics

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sapientia Pharmaceuticals
  • Developer BriaCell Therapeutics Corp
  • Class Antifibrotics; Antineoplastics; Small molecules
  • Mechanism of Action Protein kinase C delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Systemic scleroderma

Most Recent Events

  • 13 Nov 2017 BriaCell Therapeutics receives patent allowance for protein kinase C delta (PKCd) inhibitor technology in USA and European Union
  • 24 Jul 2017 Sapientia announces intention to submit IND to US FDA within 2 years (Sapientia Pharmaceuticals Pipeline, July 2017)
  • 24 Jul 2017 Sapientia Pharmaceuticals has been acquired and merged into BriaCell Therapeutics Corp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top